How to Compare Microbiome Tests: The 7 Criteria That Actually Matter

Gut microbiome tests in Germany range from around €40 to well over €300, and from the outside, their websites look remarkably similar: a tube, a lab, a colorful report. Underneath, the differences are enormous: in what is measured, how precisely, and what you can actually do with the result.

Full disclosure before we start: we sell one of these tests. That makes us biased, which is exactly why this article is not a ranking of named providers, but something more durable: the seven criteria that objectively separate deep analyses from crude ones, plus a checklist you can hold against any provider. Including us: our complete demo report is public (www.my.bactera.de/demo) so you can verify every claim yourself.

First, the honest part: what no self-test can do

Consumer advocates have repeatedly criticized microbiome self-tests, and where tests promise medical diagnoses or claim to tell you “exactly what to eat”, that criticism is deserved. So let's set the boundary clearly: no stool self-test diagnoses a disease, and none replaces a doctor's visit. Microbiome science is young; serious providers say so.

What a good analysis can do: show the state of your gut ecosystem (which microbes live there, how diverse the community is, which functional capacities it carries) and give you a measurable baseline you can track over time. That is genuinely useful. It is also the standard against which every criterion below is measured. If a provider promises more than that, walk away, regardless of price.

Criterion 1: The sequencing technology

This is the single biggest quality difference, and most product pages bury it. There are three tiers:

Targeted panels (qPCR or culture) look only for a predefined shortlist of microbes. Cheap, but blind to everything not on the list.

16S rRNA sequencing reads a single bacterial “barcode” gene. It's cost-efficient and widespread (many consumer tests use it), but it has structural limits: it captures bacteria only (no fungi, viruses or parasites), and the short gene regions typically sequenced cannot reliably distinguish species: resolution usually ends at genus level [2].

Shotgun metagenomics sequences all DNA in the sample. Head-to-head comparisons show that 16S detects only part of the community that shotgun sequencing reveals, and that shotgun is markedly better at finding less abundant organisms [1]. It resolves down to species (and often strain) level, covers non-bacterial organisms, and reads functional genes, which is why it's the method behind landmark clinical microbiome studies [3,4]. We've explained the technical differences in detail in our 16S vs. shotgun guide.

Criterion 2: Resolution: genus or species?

Why does species-level matter? Because within one genus, species can play opposite roles. Escherichia contains harmless lifelong companions and serious pathogens. And in a large ME/CFS study, it was the abundance of one specific species, Faecalibacterium prausnitzii, that tracked with symptom severity [4]. A genus-level report averages such signals away. Ask every provider directly: “Do you report at species level, and with which method?” If the answer is short-read 16S, species-level claims deserve skepticism [2].

Criterion 3: What's covered beyond bacteria?

Your gut hosts more than bacteria: yeasts and fungi (like Candida or Malassezia), viruses and bacteriophages, archaea (including the methane producers relevant for bloating and constipation), sometimes parasites like Giardia intestinalis, plus a layer most tests ignore entirely: antibiotic resistance genes, whose dynamics researchers tracked in the famous antibiotic-recovery study [3]. A 16S-based test cannot see any of this by design. If fungi, pathogens or your resistome matter to you, the method has to be shotgun, or you're paying for a bacteria-only snapshot.

Criterion 4: Composition or function?

Knowing who lives in your gut is step one. The more clinically interesting question is what your community can do: How much capacity does it have to produce butyrate and other short-chain fatty acids? How much potential for gas formation? The ME/CFS study above is a good illustration. Its key finding wasn't a species list but a functional deficit: a measurably reduced microbial capacity for butyrate synthesis [4]. Ask providers whether their report includes functional analysis or taxonomy only.

Criterion 5: Report depth and transparency

A good report translates data into understandable, prioritized insights and still gives you access to the underlying detail: the full species list, the actual values. The fastest transparency test for any provider: do they show you a complete demo report before you buy? Not marketing screenshots, but the real thing. If a provider won't show you what you'll actually receive, that tells you something. (Ours is here, in full: www.my.bactera.de/demo)

Criterion 6: Lab, location and data protection

A stool sample is intimate data. Ask: Where is the sample analyzed, in Germany/the EU or shipped abroad? Does the provider work under GDPR? What happens to your sample and your sequence data after analysis, and can you have both deleted? Serious providers answer these questions in writing on their site.

Criterion 7: Price versus scope

Simple bacteria-only tests typically sit in the lower price range, deep multi-domain shotgun analyses cost more. That's not a scandal, it's sequencing economics. The honest guidance: pay only for scope you'll use. If you want a rough bacterial snapshot out of curiosity, a basic test can be enough. If you're investigating persistent symptoms, want fungi, pathogens, resistance genes and functional capacity covered, or plan before/after tracking of a dietary change, the deeper method is what you're actually paying for.

The checklist: 7 questions for any provider

• Which sequencing method: targeted panel, 16S or shotgun metagenomics?
• Is the analysis resolved at species level, and does the method support that claim?
• Are fungi, viruses, archaea and parasites covered, or bacteria only?
• Are antibiotic resistance genes included?
• Is there functional analysis (e.g., butyrate/short-chain fatty acid capacity, gas formation), or taxonomy only?
• Is a complete demo report publicly viewable before purchase?
• Where is the sample analyzed, what happens to sample and data afterwards, and is everything GDPR-compliant?

Where Bactera stands on these criteria

Measured against this list, transparently: our Microbiome 360° analysis uses shotgun metagenomics at species-level resolution; it covers bacteria, fungi (including Candida and Malassezia), viruses and phages, archaea and parasites such as Giardia; it screens antibiotic resistance genes; it includes functional analysis such as short-chain fatty acid and gas-formation potential; the full demo report is public (www.my.bactera.de/demo); and samples are analyzed in Germany under GDPR. You can see the packages here, and we genuinely encourage you to hold the same seven questions against every other provider you're considering. That comparison is one we're happy to be part of.

The bottom line

Microbiome tests differ less in their marketing than in their method. The technology decides what can be seen at all; species-level resolution and functional analysis decide whether the results connect to the actual research; and transparency (a public demo report, clear data policies) decides whether you can trust what you're buying. Seven questions separate a deep analysis from an expensive bacteria snapshot. Ask all seven, every time, no matter whose test ends up in your cart.

This article is for informational purposes only and is not medical advice. Microbiome self-tests (including ours) do not diagnose diseases and do not replace medical care. Persistent symptoms belong in a doctor's office first.

Scientific references

1. Durazzi F, Sala C, Castellani G, Manfreda G, Remondini D, De Cesare A. Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. Scientific Reports. 2021;11(1):3030. DOI: 10.1038/s41598-021-82726-y
2. Johnson JS, Spakowicz DJ, Hong BY, et al. Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis. Nature Communications. 2019;10:5029. DOI: 10.1038/s41467-019-13036-1
3. Palleja A, Mikkelsen KH, Forslund SK, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology. 2018;3(11):1255-1265. DOI: 10.1038/s41564-018-0257-9
4. Guo C, Che X, Briese T, et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host & Microbe. 2023;31(2):288-304.e8. DOI: 10.1016/j.chom.2023.01.004